{"@type":"dcat:Dataset","accessLevel":"public","bureauCode":["009:38"],"contactPoint":{"fn":"Health Data Initiative","hasEmail":"mailto:mmrr-editors@cms.hhs.gov"},"description":"<p>Non-compliance was found to be lower than previously reported. Patients who are male, age 65 to 74, Black, or residing in the South are associated with higher noncompliance for cardiovascular medications among the therapeutic classes we studied. Dual eligibility enrollment is typically associated with improved compliance, enrollment in a Medicare Advantage Prescription Drug (MAPD) plan may or may not improve compliance dependent on the therapeutic class under study. Increased disease burden is associated with lower compliance. OOP non-class costs had an opposing effect on compliance as compared to OOP daily costs, higher OOP non-class costs were associated with better compliance.</p>\n","distribution":[{"@type":"dcat:Distribution","downloadURL":"http://www.cms.gov/mmrr/Articles/A2011/mmrr-2011-001-04-a05.html","mediaType":"application/unknown","title":"Resource","identifier":"resource-eca80043-a304-4707-8aba-2c7c84d5d296","interra-published":true}],"identifier":"325","keyword":["Prescription Drug Plans"],"language":["en"],"license":"http://opendefinition.org/licenses/odc-odbl/","modified":"2016-07-22","programCode":["009:000"],"publisher":{"@type":"org:Organization","name":"Centers for Medicare &amp; Medicaid Services"},"title":"Noncompliance in the Use of Cardiovascular Medications..."}
